Alain Munoz
Venture Partner @ Idinvest Partners
Dijon, France
Alain Munoz is a Chairman of the Board at Acticor Biotech.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Alain Munoz invests in
Stages Alain Munoz invests in
Countries Alain Munoz invests in
Investment Focus
Industry
- Biotechnology 2 (100%)
- Pharmaceutical 2 (100%)
- Biopharma 1 (50%)
- Health Care 1 (50%)
- Therapeutics 1 (50%)
Country
- France 1 (50%)
- United States 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Acticor Biotech
|
Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $8.7M / Post-IPO Equity / Mar 15, 2024 | |
Santen Pharmaceutical
|
Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions. | $16.5M / Post-IPO Equity / Sep 26, 2009 |
Co-Investors
About Idinvest Partners
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Idinvest Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alain Munoz
Venture Partner
|
|||
Alban Wyniecki
Managing Director
|
|||
Benoist Grossmann
Managing Director
|
|||
Chloe Giard
Investment Director
|
|||
Louis Bô
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Alain Munoz invest in?
Alain Munoz invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Post-IPO Equity stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alain Munoz last invest?
The most recent investment recorded for Alain Munoz closed in Mar 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
